Brobeck Docket No.: 030639.0043.U

1653

Group Art Unit:

Examiner: Mohamed, A.A.

Atty. Docket No.: 231/181 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

pplicant:

Beeley, et al.

Serial No.:

09/003,869

Filed:

January 7,m 1998

Title: USE OF EXENDINS AND AGONISTS

THEREOF FOR THE REDUCTION OF

FOOD INTAKE

Commissioner of Patents and Trademarks Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, the items identified in this Supplemental Information Disclosure Statement ("IDS") are brought to the attention of the Office. The items are listed on the attached form PTO/SB/08A and copies are enclosed.

The items identified in this Supplemental IDS may or may not be "material" pursuant to 37 C.F.R. § 1.56. The submission thereof by Applicant is not to be construed as an admission that any such patent, publication or other information referred to therein is material or considered to be material (37 C.F.R. § 1.97(h)), or even qualifies as "prior art" under 35 U.S.C. § 102 with respect to this invention unless specifically designated by Applicant as such.

This IDS is believed to be properly submitted under 37 C.F.R. § 1.97(c)(2), and the Commissioner is authorized to charge deposit account 010535 for the fee required under 37 C.F.R. § 1.17(p).

CERTIFICATE OF MAILING (37 C.F.R. §1.10)

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage in an envelope addressed to the Commissioner for Patents, Patent and Trademark Office, Washington, D.C. 20231.

Amanda J. Halverson Name of Person Mailing Paper November 7, 2002 Date of Deposit Signature of Person Mailing Paper Ţ

Should any fees or credits become due during the pendency of this application, the Commissioner is hereby authorized to charge or credit any such fees to Amylin Pharmaceuticals, Inc.'s Deposit Account No. 01-0535.

Respectfully submitted,

AMYLEN PHARMACEUTICALS, INC

Molly A. Holman, Ph.D. Registration No.: 40,022

Amylin Pharmaceuticals, Inc. 9373 Towne Centre Drive Suite 250 San Diego, California 92121 (858) 552-2200 telephone (858) 552-2212 fax